Consideration of Inherited Cancer Risk on a Continuum

Description

Germline pathogenic variants (GPVs) in cancer susceptibility genes (CSGs) vary in their penetrance across organ sites and resultant influence on clinical management. Overall cancer risk in an individual with a GPV in a CSG can vary widely due to contributions from genetic factors such as the specific variant, wider genomic context (e.g., common risk alleles comprising polygenic risk scores), and modifiable and non-modifiable factors, including but not limited to, family history, age, environment, lifestyle, and hormonal factors. Cancer risk perception for an individual can be influenced by factors such as personal context, experience of hereditary cancer risk, and subjective experience of risk. The threshold for clinical intervention to either reduce cancer risk or initiate cancer surveillance requires assimilation of all contributing risk factors, consideration of medical context (i.e., other competing risks, such as comorbidities) and personalized counseling to enable individualized cancer risk management.

Level of Instruction
Intermediate - Refresher course; some basic knowledge of subject recommended
 

Learning Objectives

1. Describe the various factors that influence inherited cancer risk.
2. Describe the various factors that may guide cancer risk management.
3. Describe examples of variants in genes that deviate from typical gene-specific risks.

Course summary

Available credit: 
  • 0.10 NSGC CEU
Course opens: 
03/04/2026
Course expires: 
03/04/2028
Cost:
$0.00

Presenter: Tuya Pal, MD, FACMG

Professor of Medicine and an Ingram Professor of Cancer Research at the Vanderbilt University Medical Center

Tuya Pal, M.D. is a Professor of Medicine and an Ingram Professor of Cancer Research at the Vanderbilt University Medical Center, where she is also the Associate Director for Clinical Genomics at the Vanderbilt Ingram Cancer Center. She is a board-certified practicing clinical cancer geneticist, and also the Vice Chair of the National Comprehensive Cancer Network Genetics/Familial Guidelines Committee for Breast, Ovarian, Pancreatic, and Prostate Cancer. Her research has focused on genomics, etiology, outcomes, and care delivery among individuals with inherited cancer, including young Black women with breast cancer.

 

Moderator: Katherine Crawford, MS, CGC

Clinical Science Liaison at Ambry Genetics

Katie is a Clinical Science Liaison at Ambry Genetics working with oncology, rare disease, and exome. She has previously worked clinically at Women & Infant's Hospital of Rhode Island for over five years as an oncology genetic counselor. She is a graduate of the Arcadia University Genetic Counseling Program and has numerous scientific publications in the fields of oncology, neurology, epidemiology, and psychiatry.

Educational Independence and Disclosure Policy

EducateNext is committed to providing independent, objective, and evidence-based educational content. None of the individuals in control of this content—including our planners, reviewers, and approval faculty—have any financial relationships with ineligible companies to disclose. For all educational sessions, speaker-specific disclosures regarding any potential conflicts of interest are required and will always be shared directly with learners at the beginning of their respective presentations.

Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Programs.

Credit eligibility varies by activity; please see below for the specific credit types offered for this course.

Available Credit

  • 0.10 NSGC CEU

Price

Cost:
$0.00
Please login or register to take this course.
  • Click above to register for and complete this activity.
  • You can review your pending and completed registrations at any time by going to My Account > My Activities.

Please note: Attendees must track continuing education (CE) credits towards recertification. Credit cannot be claimed for both live and recorded versions of the same webinar; attendance is cross-checked annually. We apologize for the inconvenience and are working toward a single-platform solution to automatically manage dual registration and integrated transcript tracking.